Contraindicated in:
Use Cautiously in:
CV: ARTERIAL THROMBOEMBOLIC EVENTS (INCLUDING MI) , hypertension.
Endo: hypothyroidism.
GI: GASTROINTESTINAL PERFORATION, HEPATOTOXICITY, abdominal pain, ↓appetite, diarrhea, ↑bilirubin, ↑liver enzymes, nausea, vomiting, ↓ weight.
Hemat: bleeding.
Neuro: headache.
Drug-Drug:
Drug-Natural Products:
Hepatic Impairment
Therapeutic Classification: pulmonary fibrosis agents
Pharmacologic Classification: kinase inhibitors
Absorption: 4.7% absorbed following oral administration (substantial first-pass effect).
Distribution: Unknown.
Protein Binding: 97.8%.
Metabolism/Excretion: Undergoes extensive metabolism and subsequent fecal/biliary elimination (93.4%). Minimal amounts excreted in urine.
Half-life: 9.5 hr.
NDC Code*